ORIVA

Oriva is a biotechnology company developing a novel platform for the oral delivery of biologics, such as peptides and proteins, which are traditionally administered via injection. Their technology utilizes a mucoadhesive patch system designed to adhere to the intestinal wall and facilitate the transport of large molecules into the bloodstream. By transforming injectable therapies into oral pills, Oriva aims to improve patient compliance and expand access to life-changing treatments for chronic conditions like diabetes and autoimmune diseases. The company's proprietary approach protects sensitive therapeutic payloads from the harsh environment of the gastrointestinal tract. Oriva is currently in the pre-clinical stage, focusing on validating its platform with high-value therapeutic candidates like GLP-1 receptor agonists. The company was founded by leading researchers from Harvard University and is backed by prominent venture capital firms.